ST elevation myocardial infarction in pregnancy

Jump to navigation Jump to search

Acute Coronary Syndrome Main Page

ST Elevation Myocardial Infarction Microchapters

Home

Patient Information

Overview

Pathophysiology

Pathophysiology of Vessel Occlusion
Pathophysiology of Reperfusion
Gross Pathology
Histopathology

Causes

Differentiating ST elevation myocardial infarction from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Natural History and Complications

Risk Stratification and Prognosis

Pregnancy

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples

Chest X Ray

Cardiac MRI

Echocardiography

Coronary Angiography

Treatment

Pre-Hospital Care

Initial Care

Oxygen
Nitrates
Analgesics
Aspirin
Beta Blockers
Antithrombins
The coronary care unit
The step down unit
STEMI and Out-of-Hospital Cardiac Arrest
Pharmacologic Reperfusion
Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI)
Fibrinolysis
Reperfusion at a Non–PCI-Capable Hospital:Recommendations
Mechanical Reperfusion
The importance of reducing Door-to-Balloon times
Primary PCI
Adjunctive and Rescue PCI
Rescue PCI
Facilitated PCI
Adjunctive PCI
CABG
Management of Patients Who Were Not Reperfused
Assessing Success of Reperfusion
Antithrombin Therapy
Antithrombin therapy
Unfractionated heparin
Low Molecular Weight Heparinoid Therapy
Direct Thrombin Inhibitor Therapy
Factor Xa Inhibition
DVT prophylaxis
Long term anticoagulation
Antiplatelet Agents
Aspirin
Thienopyridine Therapy
Glycoprotein IIbIIIa Inhibition
Other Initial Therapy
Inhibition of the Renin-Angiotensin-Aldosterone System
Magnesium Therapy
Glucose Control
Calcium Channel Blocker Therapy
Lipid Management

Pre-Discharge Care

Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT

Post Hospitalization Plan of Care

Long-Term Medical Therapy and Secondary Prevention

Overview
Inhibition of the Renin-Angiotensin-Aldosterone System
Cardiac Rehabilitation
Pacemaker Implantation
Long Term Anticoagulation
Implantable Cardioverter Defibrillator
ICD implantation within 40 days of myocardial infarction
ICD within 90 days of revascularization

Case Studies

Case #1

Case #2

Case #3

Case #4

Case #5

ST elevation myocardial infarction in pregnancy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ST elevation myocardial infarction in pregnancy

CDC on ST elevation myocardial infarction in pregnancy

ST elevation myocardial infarction in pregnancy in the news

Blogs on ST elevation myocardial infarction in pregnancy

Directions to Hospitals Treating ST elevation myocardial infarction

Risk calculators and risk factors for ST elevation myocardial infarction in pregnancy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Physiological changes during pregnancy may increase the woman's risk of developing a myocardial infarction (MI). MI during the antepartum period is usually caused by an atherosclotic plaque rupture, whereas MI during the peripartum and postpartum period is usually caused by coronary artery dissection (commonly in the LAD). Diagnosis of MI among pregnant women is similar to that in the general population and requires clinical suspiccion, as well as ECG changes and troponin elevation. In contrast, elevated CK-MB concentration is unreliable, since CK-MB may normally increase during labor and post-delivery due to non-cardiac causes, namely placental and uterine leaks. During an MI, echocardiography is safe and may be performed to evaluate wall motion abnormalities, and fetal monitoring is recommended. Treatment is usually by percutaneous coronary intervention. If spontaneous coronary artery dissection occurs, a more thorough investigation for connective tissue diseases and vasculitis is warranted.

Acute MI in Pregnancy

  • Incidence: 1 per 35,000 deliveries
  • Maternal mortality rate: 5% to 18%, fetal mortality rate: 9%
  • Common in third trimester until 1-2 months post-delivery
  • Antepartum: Atherosclotic plaque rupture is the most common cause
  • Perpartum or postpartum: Coronary artery dissection (LAD > RCA > LC > LM)

Risk Factors

  • It is unknown if pregnancy itself is a risk factor in development of acute MI.
  • The most important risk factors in the development of AMI in pregnancy are generally similar to those in the general population. Risk factors include:
  • Age > 35 years
  • Diabetes mellitus
  • Hypertension
  • Smoking
  • Connective tissue diseases (e.g. Ehler Danlos syndrome)
  • Vasculitis (e.g. Takayasu arteritis)
  • Thrombophilia (e.g. antiphospholipid syndrome)
  • Acute post-partum stress:
  • Severe post-partum hemorrhage
  • Post-partum infection

Pathophysiology

  • During pregnancy, progesterone release results in structural changes in the vascular intima and media.
  • Physiologically, cardiac output and blood volume increase during pregnancy, both of which may increase the risk of cardiovascular events.

Diagnosis

  • Diagnosis similar to the general population by: Symptoms, ECG changes, and troponin.
  • CK-MB concentrations may markedly increase during labor and post-delivery due to non-cardiac causes, namely placental and uterine leaks.
  • To view common normal physiological changes on ECG in pregnancy (may mimic AMI), click here.
  • To view normal physiological changes in biomarker concentrations during labor and delivery: for troponin, click here | for CK-MB, click here.
  • Echocardiography is safe and may be performed to evaluate wall motion abnormalities.
  • Fetal monitoring is recommended.

Treatment